2,2',4,6'-tetramethoxystilbene

potent inhibitor of human cytochrome P450 1B1; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Leukemia 01/01/2018 - "Treatment with 2,2',4,6'-tetramethoxystilbene (TMS), a specific CYP1B1 inhibitor, significantly inhibited cell viability in human breast cancer and leukemia cell lines, including MCF-7, MDA-MB-231, HL-60, and U937 cells. "
2.	Pulmonary Hypertension 01/01/2019 - "Oestrogen metabolism through cytochrome P450 1B1 (CYP1B1) was inhibited with 2,2',4,6'-tetramethoxystilbene (TMS).ob/ob mice spontaneously develop pulmonary hypertension, pulmonary vascular remodelling and increased reactive oxygen species production in the lung; these effects were attenuated by ANA. "
3.	Breast Neoplasms (Breast Cancer) 01/01/2018 - "Treatment with 2,2',4,6'-tetramethoxystilbene (TMS), a specific CYP1B1 inhibitor, significantly inhibited cell viability in human breast cancer and leukemia cell lines, including MCF-7, MDA-MB-231, HL-60, and U937 cells. "

1.	Reactive Oxygen Species (Oxygen Radicals)
2.	Cytochrome P-450 Enzyme System (Cytochrome P450)